Correlations of telomere length, telomerase activity, and telomerlc-repeat binding factor 1 expression in colorectal carcinoma: Prognostic indications

Cancer

Volumn 106, Issue 3, 2006, Pages 541-551

  Garcia Aranda, Cristina ^a   De Juan, Carmen ^a   Diaz Lopez, Antonio ^a   Sanchez Pernaute, Andres ^b   Torres, Antonio Jose ^b   Diaz Rubio, Eduardo ^b   Balibrea, Jose Luis ^b   Benito, Manuel ^a   Iniesta, Pilar ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Colorectal carcinoma; Prognosis; Telomerase activity; Telomere status; Telomeric repeat binding factor 1 expression

Indexed keywords

TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CELL IMMORTALIZATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REACTIVATION; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT; RISK ASSESSMENT; TELOMERE; TUMOR CELL;

AGED; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TELOMERASE; TELOMERE; TELOMERIC REPEAT BINDING PROTEIN 1;

EID: 31544438868     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21625     Document Type: Article

References (31)

1. De la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer. 2004;4:769-779.
2. Cohen AM, Minsky BD, Schilsky RL. Cancer of the colon and cancer of the rectum. In: De Vita VT Jr., Hellmann S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 5th ed. Philadelphia: J.B. Lippincott Company, 1997: 1144-1228.
3. Engelhardt M, Drullinsky P, Guillem J, Moore MA. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res. 1997;3:1931-1941.
4. Neumann AA, Reddel RR. Telomere maintenance and cancer-look, no telomerase. Nat Rev Cancer. 2002;2:879-884.
5. Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol. 2003;21:2034-2043.
6. Sedivy JM. Can ends justify the means? Telomeres and the mechanisms of replicative senescence and immortalization in mammalian cells. Proc Natl Acad Sci USA. 1997;95:9078-9081.
7. Ulaner GA. Telomere maintenance in clinical medicine. Am J Med. 2004;117:262-269.
8. Meeker AK, Hicks JL, Jacobuzio-Donahue CA, et al. Telomere length abnormalities occur early in the iniciation of epithelial carcinogenesis. Clin Cancer Res. 2004;10:3317-3326.
9. Zhou XZ, Perrem K, Lu KP. Role of Pin2/TRF1 in telomere maintenance and cell cycle control. J Cell Biochem. 2003;89: 19-37.
10. Turnbull RB, Watson FR, Spratt J. Cancer of the colon: the influence of the no-touch isolation technique on survival rates. Ann Surg. 1967;166:420-427.
11. Sobin L. The World Health Organization's histological classification of lung tumors: a comparison of the first and second editions. Cancer Detect Prev. 1982;5:391-406.
12. Gonzalez-Quevedo R, de Juan C, Massa MJ, et al. Detection of telomerase activity in human carcinomas using a TRAP-ELISA method: correlation with hTR and hTERT expression. Int J Oncol. 2000;16:623-628.
13. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
14. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res. 1976;3:2303-2308.
15. Gonzalez-Quevedo R, Iniesta P, Moran A, et al. Cooperative role of telomerase activity and p!6 expression in the prognosis of non-small cell lung cancer. J Clin Oncol. 2002;20: 254-262.
16. Boldrini L, Faviana P, Gisfredi S, et al. Evaluation of telomerase in the development and progression of colon cancer. Int J Mol Med. 2002;10:589-592.
17. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787-791.
18. Gertler R, Rosenberg R, Stricker D, et al. Telomere length and Human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 2004;22:1807-1814.
19. Nakamura KI, Furugori E, Esaki Y, et al. Correlation of telomere lengths in normal and cancer tissue in the large bowel. Cancer Lett. 2000;158:179-184.
20. Takagi S, Kinouchi Y, Hiwatashi N, et al. Telomere shortening and the clinicopathologic characteristics of human colorectal carcinomas. Cancer. 1999;86:1431-1436.
21. Engelhardt M, Albanell J, Drullinsky P, et al. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of colon, prostate and sarcoma. Clin Cancer Res. 1997;3:1849-1857.
22. Matthews P, Jones CJ, Skinner J, Haughton M, de Micco C, Wynford-Thomas D. Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications. J Pathol. 2001;194:183-193.
23. Hiroshima T, Komiya T, Nitta T, et al. Prognostic significance of telomeric repeat length alterations in pathological Stage I-IIIA non-small cell lung cancer. Anticancer Res. 2000; 20(3B):2181-2187.
24. Patel MM, Parekh LJ, Jha FP, et al. Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Head Neck. 2002;24:1060-1067.
25. Wu KD, Orme LM, Shaughnessy I Jr., Jacobson J, Barlogie B, Moore MA. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status and overall survival. Blood. 2003;101:4982-4989.
26. van Steensel B, de Lange T. Control of telomere length by human telomeric protein TRF1. Nature. 1997;385:740-743.
27. Matsutani N, Yokozaki H, Tahara E, et al. Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int J Oncol. 2001;19:507-512.
28. Ohyashiki JH, Hayashi S, Yahata N, et al. Impaired telomere regulation mechanism by TRF1 (telomere-binding protein), but not TRF2 expression, in acute leukaemia cells. Int J Oncol. 2001;18:593-598.
29. Smogorzewska A, van Steensel B, Bianchi A, et al. Control of human telomere length by TRF1 and TRF2. Mol Cell Biol. 2000;20:1659-1668.
30. Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res. 2000;6:2696-2701.
31. Gertler R, Rosenberg R, Stricker D, et al. Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor and nontumorous mucosa from patients with colorectal carcinoma. Cancer. 2002;95:2103-2111.